Skip to Content
Official Responses Archive

The British Association of Dermatologists is invited to comment on a large number of consultation documents each year. These documents are issued by government departments, regulatory bodies and various other organisations around the UK. Please click on any of the "+" symbols in the list below for our archived official responses to the Department of Health, General Medical Council, All Party Parliamentary Group, NICE, MHRA and other professional bodies.

Close
NICE Interventional Procedures Consultation: Electrochemotherapy for metastases in the skin (of non-skin origin and melanoma)
Close
Review of the Regulation of Cosmetic Interventions

Visit the GOV.UK website to see the review.

Close
Draft Mandate to the NHS Commissioning Board

Visit the GOV.UK website to see then consultation

Close
NICE Draft Clinical Guideline Consultation: Psoriasis
Close
NICE Draft Scope for Clinical Guidelines: Pressure Ulcers - prevention and management of pressure ulcers in primary and secondary care
Close
NICE Briefing Note on 'Management of Non-Melanomas in Skin Cancer': Topic Selection
Close
Royal College of Paediatrics and Child Health consultation: Eczema Care Pathway
Close
NICE Appraisal Consultation Document (ACD) for the Single Technology Appraisal: Golimumab for the treatment of psoriatic arthritis
Close
NICE Draft Public Health Intervention Guidance consultation: Skin Cancer Prevention: Information, Resources and Environmental Changes
Close
NICE Technology Appraisal Guidance Nos 103/ 134/ 146

Review of NICE Technology Appraisal Guidance Nos 103/ 134/ 146; on the use of etanercept and efalizumab for the treatment of adults with psoriasis, infliximab for the treatment of psoriasis and adalimumab for the treatment of psoriasis

Close
MHRA consultation: MLX 342: Proposals to amend Section 58 of the Medicines Act 1968 to enable UK Pharmacists to dispense prescription only medicines prescribed by Doctors and Dentists registered in European member states and Switzerland
Close
NICE Single Technology Appraisal: Adalimumab for the treatment of psoriatic arthritis (Sep 2007)

Please note this evidence is similar to that given to NICE in Nov 2006

Back to top